Vertex Earnings: Stock's Turnaround Hinges on Q1 Results

Vertex Pharmaceuticals first quarter earnings, set to be released Monday, have investors on edge. Last quarter, they missed earnings estimates but beat revenue projections. Analysts predict a six point five percent revenue increase this time, yet Vertex has consistently missed revenue targets in the past. The biotech sector has seen significant growth, with peers like Moderna and Biogen exceeding expectations. Vertex stock has dipped, trading around $423, with analysts holding an average price target of $548. Earnings could provide the boost Vertex needs to turn their fortunes around. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/47f627265651fb8e